🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› London
Clinical trial register · Canada

Clinical Trials in London, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Canada and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 6540 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:55 UTC
6540
Studies in scope
all four open statuses
3515
Recruiting now
open to new participants
887
Lead sponsors
across recruiting studies
Top sites
Toronto 43 Montreal 25 London 23 Calgary 22 Hamilton 20
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's108 Western University, Canada39 AstraZeneca36 Novartis Pharmaceuticals24 Eli Lilly and Company23 Clear sponsor filter
Site location
Toronto43 Montreal25 London23 Calgary22 Hamilton20
All 71 locations
Target enrolment
to

Trials with a site in London

23 of 6540 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Canada
Start
Recruiting
A Substudy of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis
NCT07571174Amyotrophic Lateral Sclerosis
DrugLY4256984
Eli Lilly and Company
Phase 1
32
Calgary, London, Montreal, Toronto
2026-05-14
Recruiting
A Master Protocol (OLMP): A Study of LY4256984 in Participants With Amyotrophic Lateral Sclerosis (ALS)
NCT07571200Amyotrophic Lateral Sclerosis
DrugLY4256984
Eli Lilly and Company
Phase 1
32
Calgary, London, Montreal, Toronto
2026-05-14
Recruiting
A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
NCT07483099Crohn Disease
DrugsLY4395089·Mirikizumab
Eli Lilly and Company
Phase 2
60
Lethbridge, London, Vaughan
2026-05-04
Recruiting
A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
NCT07483073Colitis, Ulcerative, Crohn Disease
DrugsLY4395089·Mirikizumab
Eli Lilly and Company
Phase 2
60
Lethbridge, London, Vaughan
2026-05-04
Recruiting
A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
NCT07533019Vitiligo, Non-Segmental Vitiligo (NSV)
DrugLY4005130
Eli Lilly and Company
Phase 2
66
Chicoutimi, London, Ottawa, Richmond Hill, Toronto, Verdun
2026-04-14
Recruiting
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
NCT07415044Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
DrugZotemtegrast
Eli Lilly and Company
Phase 2
1,431
Greater Sudbury, Halifax, London
2026-03-26
Recruiting
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
NCT07222332Diabetes Mellitus, Type 1
DrugBaricitinib
Eli Lilly and Company
Phase 3
300
Calgary, Chicoutimi, Edmonton, London, Ottawa, Québec, Vancouver
2026-02-05
Active, closed
A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight
NCT07357415Obesity, Overweight
DrugRetatrutide
Eli Lilly and Company
Phase 3
600
Brampton, Courtice, Hamilton, Joliette, London, Québec, Sherbrooke, Toronto
2026-01-24
Recruiting
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
NCT07186101Ulcerative Colitis
DrugsZotemtegrast·Mirikizumab
Eli Lilly and Company
Phase 2
252
Hamilton, London, Mississauga, Trois-Rivières
2025-11-10
Recruiting
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
NCT07165028Metabolic Dysfunction-Associated Steatotic Liver Disease
DrugsRetatrutide·Tirzepatide
Eli Lilly and Company
Phase 3
4,500
Calgary, Chicoutimi, Edmonton, Halifax, London, North Bay, Québec, Toronto
2025-10-15
Recruiting
A Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis
NCT07100119ALS (Amyotrophic Lateral Sclerosis)
DrugLY4256984
Eli Lilly and Company
Phase 1
32
Calgary, Edmonton, London, Montreal, Toronto
2025-08-05
Recruiting
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
NCT06937086Ulcerative Colitis, Obesity or Overweight
DrugsMirikizumab·Tirzepatide
Eli Lilly and Company
Phase 3
350
London, Montreal, Ottawa, Vancouver
2025-06-26
Recruiting
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
NCT06937099Crohn's Disease, Obesity or Overweight
DrugsMirikizumab·Tirzepatide
Eli Lilly and Company
Phase 3
290
Edmonton, London, Montreal, Ottawa, Vancouver
2025-06-26
Active, closed
A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden
NCT07006792Atopic Dermatitis
DrugLebrikizumab
Eli Lilly and Company
Phase 4
233
Fredericton, Halifax, London, Nanaimo, Ottawa, Peterborough, Sherbrooke, Thunder Bay
2025-06-16
Recruiting
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
NCT06598943Ulcerative Colitis, Ulcerative Colitis Chronic
DrugsEltrekibart·Mirikizumab
Eli Lilly and Company
Phase 2
143
London, Montreal
2024-10-10
Active, closed
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
NCT06383390Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
DrugRetatrutide
Eli Lilly and Company
Phase 3
10,000
Calgary, Chicoutimi, Courtice, Edmonton, London, Moncton, North York, Oshawa
2024-04-30
Recruiting
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
NCT05509777Crohn's Disease
DrugMirikizumab
Eli Lilly and Company
Phase 3
90
Halifax, London, Toronto, Vancouver
2024-03-13
Active, closed
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
NCT06292013Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
DrugLepodisiran
Eli Lilly and Company
Phase 3
17,300
Brampton, Chicoutimi, Hamilton, Joliette, London, Longueuil, Moncton, New Westminster
2024-03-05
Active, closed
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
NCT05514054Breast Neoplasms
DrugsImlunestrant·Tamoxifen·Exemestane·Anastrozole
Eli Lilly and Company
Phase 3
8,000
Calgary, London, Montreal, Québec, Surrey, Toronto
2022-10-04
Recruiting
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
NCT04844606Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease
DrugMirikizumab
Eli Lilly and Company
Phase 3
150
London, Toronto
2021-05-26
Active, closed
A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
NCT04232553Crohn's Disease
DrugMirikizumab
Eli Lilly and Company
Phase 3
996
Edmonton, Vancouver, Kentville, London, North Bay
2020-06-22
Active, closed
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
NCT03519945Ulcerative Colitis
DrugMirikizumab
Eli Lilly and Company
Phase 3
1,058
Greenfield Park, London, Montreal, New Westminster, Vancouver, Victoria
2018-07-18
Active, closed
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
NCT02107703Breast Neoplasms
DrugsAbemaciclib·Fulvestrant
Eli Lilly and Company
Phase 3
669
Calgary, London, Toronto
2014-07-22
Rows per page Showing 1–23 of 23
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Canadian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 30 September 2026. https://priyalifescience.com/clinical-trials-canada/city/london

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Canada and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 6,540 studies in total at the last sync on 26 Sep 2026, 19:55 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 23 of those studies with a site in London that also match the filters currently applied.

How many clinical trials are recruiting in London?

15 of the 23 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:55 UTC sync. A further 0 have not yet opened recruitment, 8 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (London), 23 studies
PhaseStudiesRecruitingShare
Phase 313656.5%
Phase 26626.1%
Phase 13313%
Phase 4104.3%

Most active sponsors

Lead sponsors with the most studies (London)
Lead sponsorStudiesRecruiting
Eli Lilly and Company2315
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.